OS Therapies (OSTX) Proxy Filing summary

Executive summary

• Annual Meeting of Stockholders scheduled for October 14, 2025, to be held virtually.

• Proxy materials, including the proxy statement and annual report, are available online for review.

Voting matters and shareholder proposals

• Election of six directors to serve until the 2026 annual meeting.

• Approval of issuance of common stock or warrants to Ayala Pharmaceuticals, Inc. in connection with an asset purchase, potentially exceeding 20% of outstanding shares.

• Amendment to increase authorized common stock from 50 million to 150 million shares.

• Amendment to the 2023 Incentive Compensation Plan to increase available shares from 4 million to 10 million and raise the individual grant limit.

• Approval of a shareholder rights agreement, authorizing the board to implement it as deemed appropriate.

• Ratification of MaloneBailey, LLP as independent auditor for fiscal year ending December 31, 2025.

• Other business, including potential adjournment for further proxy solicitation, may be transacted.

Board of directors and corporate governance

• Board recommends voting FOR all director nominees and all proposals.